We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
201
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$231K 0.02%
+1,300
New +$209K
ATNX
202
DELISTED
Athenex, Inc. Common Stock
ATNX
$228K 0.02%
3,807
-6,193
-62% -$451K
APTO
203
DELISTED
Aptose Biosciences, Inc.
APTO
$224K 0.02%
227
-4
-2% -$5K
IVA
204
Inventiva
IVA
$1.06B
$202K 0.01%
14,748
-252
-2% -$3.33K
GMDA
205
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$122K 0.01%
31,029
-137
-0.4% -$685
SLNO
206
DELISTED
Soleno Therapeutics
SLNO
$112K 0.01%
8,113
-51
-0.6% -$711
AMYT
207
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$81K 0.01%
+34,131
New +$385K
TRAW icon
208
Traws Pharma
TRAW
$6.85M
$57K ﹤0.01%
603
-326
-35% -$42K
BXRX
209
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$53K ﹤0.01%
68
-3
-4% -$2.61K
ABCL icon
210
CALL
AbCellera Biologics
ABCL
$1.74B
– –
-73,700
Closed -$1.62M
ACIU icon
211
AC Immune
ACIU
$223M
– –
-196,208
Closed -$1.56M
ADCT icon
212
CALL
ADC Therapeutics
ADCT
$134M
– –
-300,000
Closed -$7.3M
AFMD
213
DELISTED
Affimed
AFMD
– –
-9,310
Closed -$792K
ALEC icon
214
CALL
Alector
ALEC
$168M
– –
-22,300
Closed -$465K
ALEC icon
215
Alector
ALEC
$168M
– –
-674,723
Closed -$14.1M
ALEC icon
216
PUT
Alector
ALEC
$168M
– –
-22,300
Closed -$465K
ALLO icon
217
CALL
Allogene Therapeutics
ALLO
$649M
– –
-100,000
Closed -$2.61M
ALNY icon
218
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-300,000
Closed -$50.9M
ANAB icon
219
AnaptysBio
ANAB
$1.58B
– –
-21,553
Closed -$558K
ANVS icon
220
Annovis Bio
ANVS
$74.4M
– –
-103,527
Closed -$8.86M
ARKG icon
221
PUT
ARK Genomic Revolution ETF
ARKG
$1.57B
– –
-119,900
Closed -$11.1M
ASND icon
222
Ascendis Pharma A/S
ASND
$16B
– –
-21,825
Closed -$2.99M
BHC icon
223
CALL
Bausch Health
BHC
$2.57B
– –
-550,000
Closed -$16.1M
BHC icon
224
PUT
Bausch Health
BHC
$2.57B
– –
-250,000
Closed -$7.33M
CCCC icon
225
C4 Therapeutics
CCCC
$385M
– –
-17,600
Closed -$666K
7 8
9
10 11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.